

PTO/SB/01B (10-01)

Approved for use through 10/31/2002, OMB 065-10031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number 09/585,817  
 Filing Date June 1, 2000  
 First Named Inventor Dale B. Schenk  
 Art Unit 1847  
 Examiner Name Christopher J. Nichols  
 Attorney Docket Number 045270-005910US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CS	349 ✓	CHECK, "Battle of the Mind," <i>Nature</i> , 422:370-372 (March 2003).	
CS	350 ✓	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <i>Nature Medicine</i> , 9(4):440-452 (April 2003).	

Examiner Signature	<i>G. Hill</i>	Date Considered	7/10/2003
--------------------	----------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 508. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent, Washington, DC 20231. P.A. 3307180 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

**Complete If Known**




Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005910US

**RECEIVED**

MAY 28 2003

1500/2900

**U.S. PATENT DOCUMENTS**

U.S. PATENT DOCUMENTS					
Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
  	340	2002/0162129 A1	10-31-2002	Lannfelt	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	345	2002/0077288 A1	06-21-2001	Frangione	
	<del>345</del>	<del>03/724,642</del>	<del>11-28-2000</del>	<del>Chaffour et al.</del>	
	346	5,935,927	08-10-1999	Vitek et al.	
	353	5,824,322	10-20-1998	Balasubramanian	
	357	5,776,468 B1	07-07-1998	Hauser et al.	
	356	5,622,701	04-22-1997	Berg	
	358	5,583,112 B2	12-10-1996	Kensil et al.	

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CJN ↓ JCN	351	WO	02/34878	A2	05-02-2002			
	352	WO	02/34777	A1	05-02-2002			
	343	EP	1 172 378	A1	01-16-2002			
	344	WO	01/90182	A2	11-29-2001			
	348	WO	01/77167	A2	10-18-2001			
	341	WO	02/03911	A2	04-07-2001			
	331	WO	99/06545	A2	11-02-1999			

Examiner  
Signature

G. Mills

Date  
Considered

11/24/03

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique prior art designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PA 3307174 v1

CONSIDERED; DO NOT PRINT.



Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B (REV. 10/97)  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number 09/585,817  
Filing Date June 1, 2000  
First Named Inventor Dale B. Schenk  
Art Unit 1647  
Examiner Name Christopher J. Nichols  
Attorney Docket Number 015270-005910US

**RECEIVED**

MAY 28 2003

**TECH OE**

2900

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
CSW	332 ✓	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <i>Progress in Brain Research</i> , Van Leeuwen et al. Eds, 117:327-337 (1998).	
	333 ✓	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000)	
	334 ✓	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
	347 ✓	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <i>Infection and Immunity</i> , May:497-502 (1981).	
	335 ✓	MASLIAH et al., "A $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001).	
	359 ✓	MUNCH et al., "Potential neurotoxic inflammatory response to A $\beta$ vaccination in humans," (2002) <i>J. Neural Transm.</i> , 109:1081-1087.	
	355 ✓	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
	354 ✓	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, Medpharm Scientific Publishers, Stuttgart, Germany.	
	336 ✓	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <i>PNAS</i> , 99(8):5591-5595 (2002).	
	337 ✓	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39 (2000).	
CSW	338 ✓	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002).	

Examiner Signature

*g. licks*

Date Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3307174 v1



PTO/SB/03B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no response is required to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

**Complete If Known**

Application Number	09/585,817
Filing Date	June 1, 2003
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005910US

RECEIVED  
MAY 28 2003  
TECH CENTER 1300/2000

	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4299-4303 (1995)	
--	-----	--	--

Examiner Signature		Date Considered	11/24/03
--------------------	--	-----------------	----------

\*EXAMINER: Initials in reference considered, whether or not citation is in conformance with MPEP 809. Drawings and other material submitted in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3307174 v1

Please type a plus sign (+) inside this box +

PTO/SB/03A (08-00)

Approved for use through 10/31/2002, OMB 0051-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

## Complete if Known

Application Number 09/585,817  
 Filing Date June 1, 2000  
 First Named Inventor Schenk, Dale B.  
 Group Art Unit 1640 1647  
 Examiner Name Unassigned NICHOLS  
 Attorney Docket Number 15270J005910

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	196	6,150,061		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	2	5,958,893		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	09-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findes et al.	12-29-1998	
	9	5,851,998		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio et al.	11-17-1998	
	12	5,786,180		Konig et al.	07-29-1998	
	13	5,753,624		McMichael et al.	05-19-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	197	5,744,358		Goldhaber et al.	04-28-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
	17	5,679,348		Nesburn et al.	10-21-1997	
	18	5,645,820		Haffer et al.	07-08-1997	
	19	5,641,474		Haffer et al.	06-24-1997	
	20	5,641,473		Haffer et al.	06-24-1997	
	21	5,642,486		McConlogue et al.	05-18-1997	
	22	5,605,811		Seubert et al.	02-25-1997	
	23	5,585,100		Mond et al.	12-17-1996	
	24	5,571,500		Haffer et al.	11-05-1996	
	25	5,571,499		Haffer et al.	11-05-1996	
	175	5,441,870		Seubert et al.	04-15-1995	
	26	5,434,170		Andrulis, Jr.	07-18-1995	

Examiner Signature *Lucia S*

Date Considered 11/24/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

MAY 16 2002

RECEIVED

TECH CENTER 1600/2900

DIPE JC187  
MAY 1 1 2002  
PATENT EXAMINER

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

## Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	<del>1640</del> 1647
Examiner Name	Unassigned - NICHOLS
Attorney Docket Number	15270J005910

56	PCT	99/06066	A2	02-11-1999
57	PCT	99/27949	A1	06-10-1999
58	PCT	99/27944	A1	06-10-1999
59	PCT	99/27911	A1	06-10-1999
60	PCT	98/44955	A1	10-15-1998
61	PCT	98/07850	A2	02-26-1998
62	PCT	97/17613	A1	05-15-1997
63	PCT	96/39176	A1	12-12-1996
64	PCT	96/25435	A1	08-22-1996
65	PCT	96/18390	A1	06-20-1996
66	PCT	95/31996	A1	11-30-1995
200	PCT	95/12815	A1	05-11-1995
67	PCT	95/11994	A1	05-04-1995
68	PCT	95/11311	A1	04-27-1995
69	PCT	95/05853	A1	03-02-1995
70	PCT	95/04151	A2	02-09-1995
71	PCT	94/05615	A1	02-17-1994
72	PCT	94/01772	A1	01-20-1994
73	PCT	93/21950	A1	11-11-1993
74	PCT	93/16724	A1	09-02-1993
75	PCT	93/15760	A1	08-19-1993
76	PCT	93/14200	A1	07-22-1993
77	PCT	93/02189	A1	02-04-1993
78	PCT	92/13069	A1	08-06-1992
79	PCT	92/06708	A1	04-30-1992
80	PCT	92/06187	A1	04-16-1992
81	PCT	91/19810	A1	12-26-1991
82	PCT	91/16819	A1	11-14-1991
83	PCT	91/12816	A1	09-05-1991
84	PCT	91/08760	A1	06-27-1991
85	PCT	90/12871	A1	11-01-1990
86	PCT	90/12870	A1	11-01-1990
87	PCT	89/01343	A1	02-23-1989
88	PCT	89/06242	A1	07-13-1989
89	PCT	89/06689	A1	07-27-1989
90	PCT	89/03687	A1	05-05-1989
91	PCT	88/10120	A1	12-29-1988
92	GB	2 220 211	A	01-04-1990
93	GB	2 335 192	A	09-15-1999

Examiner Signature	<i>G. Nichols</i>	Date Considered	11/24/03
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

10

**Complete if Known**

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1660-1648
Examiner Name	Unassigned
Attorney Docket Number	15270J005910

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T? <sup>2</sup>
CO	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?" <i>Neurology</i> , 45 1441-1445 (1995)	<input checked="" type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95)	<input checked="" type="checkbox"/>
	96	BAUJ-R et al., "Interleukin-6 and $\alpha$ 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991)	<input checked="" type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000).	<input checked="" type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input checked="" type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input checked="" type="checkbox"/>
	99	BORCHIELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997).	<input checked="" type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Curr. Opin. Genet. Develop.</i> , 3: 102-109 (1993).	<input checked="" type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 Val>Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 56:112-115 (1993).	<input checked="" type="checkbox"/>
	102	CHAO et al., "Transforming Growth Factor- $\beta$ Protects human Neurons Against $\beta$ -Amyloid Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513.7 (1993)	<input checked="" type="checkbox"/>
	103	DUFF et al., "Mouse model made," <i>Nature</i> , 373: 476-477 (1995)	<input checked="" type="checkbox"/>
	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic parkinson's disease," <i>J. Neurol. Sciences</i> , 59:341-347 (1983)	<input checked="" type="checkbox"/>
	105	ELSENSTEIN et al., "Processing of the $\beta$ -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <i>Neuroscience Letters</i> , 152:185-189 (1993)	<input checked="" type="checkbox"/>
CO	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i> , 17(5) 809-815 (1996)	<input checked="" type="checkbox"/>

Examiner  
Signature

Date

Considered

11/24/03

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 608 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10**Complete if Known**

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	<del>1645</del> <u>1647</u>
Examiner Name	<del>Unassigned</del> <u>NICHOLS</u>
Attorney Docket Number	15270J005910

<u>C90</u>	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i> , 88:1779-1782 (1991).	<input type="checkbox"/>
	108	FLANDERS et al., "Altered expression of transforming growth factor- $\beta$ in Alzheimer's disease," <i>Neurology</i> , 45:1561-1569 (1995).	<input type="checkbox"/>
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <i>Nature</i> , 373(6514): 523-527 (1995).	<input type="checkbox"/>
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>TIPS</i> , 13:108-113 (1992).	<input type="checkbox"/>
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <i>J. Exp. Med.</i> , 177:1181-1186 (1993).	<input type="checkbox"/>
	112	GLENN et al., "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391: 851 (1998).	<input type="checkbox"/>
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochemical and Biophysical Research Communications</i> , 120(3): 885-896 (1994).	<input type="checkbox"/>
	114	GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <i>Biochemical and Biophysical Research Communications</i> , 122(3): 1131-1135 (1984).	<input type="checkbox"/>
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> , 349:704-706 (1991).	<input type="checkbox"/>
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <i>PNAS</i> , 93:427-432 (1996).	<input type="checkbox"/>
	190	GRAVINA et al., "Amyloid $\beta$ Protein ( $A\beta$ ) in Alzheimer's Disease," <i>J. Biol. Chem.</i> , 270(13): 7013-7016 (1995).	<input type="checkbox"/>
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <i>Vaccine</i> , 15(12/13): 1341-1343 (1997).	<input type="checkbox"/>
	118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Bram Research</i> , 601:88-94 (1993).	<input type="checkbox"/>
	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <i>Advanced Drug Delivery Reviews</i> , 28: 97-119 (1997).	<input type="checkbox"/>
<u>CB</u>	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <i>TINS</i> , 20(4): 154-159 (1997).	<input type="checkbox"/>
	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <i>Annals of Med.</i> , 28:255-258 (1996).	<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designated number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 051-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete If Known**

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1607
Examiner Name	Unassigned - NICHOLS
Attorney Docket Number	15270J005910

Sheet 6 of 10


193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ /A4-protein," <i>Biochimica Biophysica Acta</i> , 1158:120-128 (1993)	<input type="checkbox"/>
177	HELMUTH, L., "Further Progress on a $\beta$ -Amyloid Vaccine," <i>Science</i> , 289:375 (2000).	<input type="checkbox"/>
122	HISIAO et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274:99-102 (1996).	<input type="checkbox"/>
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994).	<input type="checkbox"/>
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <i>N. E. J. Medicine</i> , 333(19):1283-1284 (1995).	<input type="checkbox"/>
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <i>J. Neuroimmunology</i> , 24:173-182 (1989).	<input type="checkbox"/>
192	IWATSUBO et al., "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in Senile Plaques with End-Specific A $\beta$ Monoclonals: Evidence That an Initially Deposited Species Is A $\beta$ 42(43)," <i>Neuron</i> , 13:45-53 (1994).	<input type="checkbox"/>
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <i>Immun. Rev.</i> , 62:185-216 (1982).	<input type="checkbox"/>
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).	<input type="checkbox"/>
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1990).	<input type="checkbox"/>
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).	<input type="checkbox"/>
165	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the A $\beta$ 4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	<input type="checkbox"/>
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <i>Neurodegeneration</i> , 2:111-121 (1993).	<input type="checkbox"/>
130	LANGER, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1532 (1990).	<input type="checkbox"/>
131	LANNIFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behavioural Brain Res.</i> , 57:207-213 (1993).	<input type="checkbox"/>
132	LIMMER et al., "Mucosal Administration of A $\beta$ Peptide Decreases Cerebral Amyloid Burden in PDAPP Transgenic Mice," <i>Society for Neuroscience Abstracts</i> , vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, October 23-28, 1999.	<input type="checkbox"/>
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by 1-ipeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> , 159:1383-1392 (1997).	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 005-1-002  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10**Complete if Known**

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	<del>1040</del> 1047
Examiner Name	Unassigned <i>104005</i>
Attorney Docket Number	15270J005910

134	LOPEZ et al., "Scrum auto-antibodies in Alzheimer's disease," <i>Acta Neurol. Scand.</i> , 84 441-444 (1991).	<input type="checkbox"/>
135	MCGHEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro. Encap.</i> , 14(2): 197-210 (1997).	<input type="checkbox"/>
136	MEDA et al., "Activation of microglial cells by $\beta$ -amyloid protein and interferon- $\gamma$ ," <i>Nature</i> , 374 647-650 (1995).	<input type="checkbox"/>
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <i>J. Exp. Med.</i> , 174:791-798 (1991).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of $\beta$ -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11): 959-969 (June 1, 1997).	<input type="checkbox"/>
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	<input type="checkbox"/>
140	PARECSE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <i>Neuron</i> , 17:553-565 (September 1996).	<input type="checkbox"/>
141	PAUL et al., "Transdermal immunization with large proteins by means of ultra-deformable drug carriers," <i>Eur. J. Immunol.</i> , 25: 3521-3524 (1995).	<input type="checkbox"/>
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <i>Chemical Abstracts</i> , 120(8): pg. 652, column 1, abstract 86406a (1994).	<input type="checkbox"/>
143	QUON et al., "Formation of $\beta$ -Amyloid protein deposits in brains of transgenic mice," <i>Nature</i> , 352 239-241 (1991).	<input type="checkbox"/>
144	RASO, V.A., Grant application # 1 R43 AG 5746-01 (publication date unknown).	<input type="checkbox"/>
145	RASO, "Immunotherapy of Alzheimer's Disease," <i>Immunotherapy Weekly</i> , Abstract (April 12, 1998).	<input type="checkbox"/>
146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <i>PNAS</i> , 89 1-5 (1992).	<input type="checkbox"/>
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <i>Annals of New York Academy of Sciences</i> , 695 198-202 (1993).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <i>J. Biol. Chem.</i> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Postischemic Hippocampus," <i>J. Biol. Chem.</i> , 269(21):15253-15257 (1994).	<input type="checkbox"/>
Examiner Signature	<i>G. Mink</i>	Date Considered
		11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/06A (08-00)

Approved for use through 10/31/2002. OMB 0661-0024  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8

of

10

## Complete If Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1640-1647
Examiner Name	Unassigned
Attorney Docket Number	15270J005910

178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer's disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999)	<input type="checkbox"/>
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000)	<input type="checkbox"/>
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994)	<input type="checkbox"/>
151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	<input type="checkbox"/>
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November 1991)	<input type="checkbox"/>
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991)	<input type="checkbox"/>
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991)	<input type="checkbox"/>
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997)	<input type="checkbox"/>
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992)	<input type="checkbox"/>
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	<input type="checkbox"/>
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997)	<input type="checkbox"/>
159	SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	<input type="checkbox"/>
160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	<input type="checkbox"/>
161	<del>SOLOMON, A., "Pro-RX (Protein Therapeutics), University of Tennessee Medical Center (publication date unknown)"</del>	<input type="checkbox"/>
162	<del>SOLOMON, B., "New Approach Towards Fast Induction of Anti <math>\beta</math>-Amyloid Peptide Immune Response," Department of Molecular Microbiology &amp; Biotechnology, Tel Aviv University Ramat Aviv, Tel Aviv, Israel</del>	<input type="checkbox"/>
162	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	<input type="checkbox"/>

CONSIDERED; DO NOT PRINT.

Examiner  
SignatureDate  
Considered

11/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initial copy of this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/06A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/585,817
Filing Date	June 1, 2000
First Named inventor	Schenk, Dale B.
Group Art Unit	164-1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	1527UJ005910

Sheet 9 of 10

184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <i>Biochem. Mol. Biol. Int.</i> , 43(3):601-611 (1997).	<input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <i>Adv. Mol. Cell Biology</i> , 15A:33-45 (1996).	<input type="checkbox"/>
186	<del>SOLOMON et al., "Activity of monoclonal antibodies in prevention of in-vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown)</del>	<input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <i>J. Neurochemistry</i> , 66:259-265 (1996).	<input type="checkbox"/>
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997).	<input type="checkbox"/>
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 94: 13287-13292 (1997).	<input type="checkbox"/>
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).	<input type="checkbox"/>
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C 37, (1994).	<input type="checkbox"/>
167	VAN GOOL et al., "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).	<input type="checkbox"/>
168	VERBEEK et al., "Accumulation of Interleukin Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Jour. Pathology</i> , 144(1):104-116 (1994).	<input type="checkbox"/>
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurol.</i> , 53(4):377-383 (1994).	<input type="checkbox"/>
180	WEN, G. Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998).	<input type="checkbox"/>
170	WENGENACK et al., "Targeting Alzheimer amyloid plaques <i>in vivo</i> ," <i>Nature Biotech.</i> , 18:868-874 (2000).	<input type="checkbox"/>
171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).	<input type="checkbox"/>
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997).	<input type="checkbox"/>
173	WOOD et al., "Amyloid precursor protein processing and A $\beta$ 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94: 1550-1555 (1997).	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

11/24/03

EXAMINER: Initial if relevant. Considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A-PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


## Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned NICHOLS
Attorney Docket Number	15270J005910

Sheet 10 of 10

	174	<del>Human Immunology &amp; Cancer Program brochure from The University of Tennessee Medical Center Graduate School of Medicine, Knoxville, Tennessee (publication date unknown)</del>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>

PA 3142468 v1

Examiner Signature		Date Considered	11/24/03
--------------------	---	-----------------	----------

<sup>1</sup> EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231